Atrial fibrillation and the pharmacological treatment: the role of propafenone

被引:1
|
作者
Sestito, A. [1 ]
Molina, E. [2 ]
机构
[1] Univ Cattolica Sacro Cuore, Sch Med, Dept Cardiol, I-00168 Rome, Italy
[2] Univ Parma, Sch Med, Dept Pharmacol, I-43100 Parma, Italy
关键词
Atrial fibrillation (AF); Acute onset AF; Prevention of AF recurrences; Antiarrhythmic drugs; Propafenone; SINUS RHYTHM; SUSTAINED-RELEASE; ORAL PROPAFENONE; MANAGEMENT; CONVERSION; EFFICACY; PREVENTION; THERAPY; TRIAL; RISK;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Atrial fibrillation is the most frequent cardiac rhythm disturbance, with prevalence increasing with age. This disease is a major risk factor for ischaemic stroke. The costs resulting from atrial fibrillation are really impressive. Pharmacological agents are the first line therapy for the management of atrial fibrillation. Antiarrhythmic drugs are used to terminate arrhythmias, as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. Among antiarrhythmic agents, drugs that inhibit early sodium current (as propafenone) are proven effective in atrial fibrillation. In this review, the most relevant data on propafenone are provided. Discussion: The development of a sustained-release formulation of propafenone allowed to reduce the wide fluctuations in plasma levels observed with the immediate release preparation, improving compliance and adherence to therapy, by simplifying the dosing regimen from 3 to 2 daily doses. Propafenone resulted an effective measure as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. In several clinical studies, strong increases of arrhythmia-free periods as well as marked increases in time to recurrence of symptomatic atrial fibrillation, such as paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation were observed. In particular, well-designed clinical studies demonstrated in large patient populations the efficacy of propafenone at several doses. At the suggested doses propafenone is usually well tolerated. Conclusion: The risk of increased occurrence of regular supraventricular arrhythmia or paroxysmal supraventricular tachycardia has been overestimated for propafenone, because this adverse event was seen in all treatment groups, including placebo, with the same (and low) frequency.
引用
收藏
页码:242 / 253
页数:12
相关论文
共 50 条
  • [41] Antiarrhythmic efficacy of propafenone in patients with persistent atrial fibrillation
    Kurbanov, R. D.
    Zakirov, N. U.
    Azizov, Sh. K.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2011, 7 (01) : 31 - 36
  • [42] Role of implantable atrial defibrillators in the treatment of atrial fibrillation
    Jordaens, LJ
    CARDIAC ARRHYTHMIAS, PACING & ELECTROPHYSIOLOGY: THE EXPERT VIEW, 1998, 201 : 265 - 270
  • [43] THE EFFECT OF INTRAVENOUS PROPAFENONE ON RAPID ATRIAL-FIBRILLATION
    CONNOLLY, SJ
    MULJI, AS
    ROGERS, DA
    SHRAGGE, BW
    DAVIS, C
    CIRCULATION, 1985, 72 (04) : 253 - 253
  • [44] Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation
    Freemantle, Nick
    Lafuente-Lafuente, Carmelo
    Mitchell, Stephen
    Eckert, Laurent
    Reynolds, Matthew
    EUROPACE, 2011, 13 (03): : 329 - 345
  • [45] Electrolyte’s imbalance role in atrial fibrillation: Pharmacological management
    Saira Rafaqat
    Sana Rafaqat
    Huma Khurshid
    Simon Rafaqat
    International Journal of Arrhythmia, 23 (1)
  • [46] The AFFIRM study and its implications for the pharmacological treatment of atrial fibrillation
    Capucci, A
    Villani, GQ
    NEW ADVANCES IN HEART FAILURE AND ATRIAL FIBRILLATION, 2003, : 179 - 181
  • [47] Malabsorption causing failure of pharmacological therapy in the treatment of atrial fibrillation
    Denton-Beaumont, Ruth N.
    Banning, Amerjeet S.
    Gershlick, Anthony H.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 128 (03) : E87 - E88
  • [49] Outcome of pharmacological treatment of patients with atrial fibrillation in the emergency room
    H Ivekovic
    V Gasparovic
    Critical Care, 7 (Suppl 2):
  • [50] Atrial fibrillation and heart failure: natural history and pharmacological treatment
    Savelieva, I
    Camm, AJ
    EUROPACE, 2004, 5 : S5 - S19